A randomized, double-blind, 2-way crossover study for Safety assessment of CVT-301 84 mg when administered with oral carbidopa/levodopa for early morning OFF symptoms in patients with Parkinson's Disease
Latest Information Update: 11 May 2018
At a glance
- Drugs Levodopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions
- 11 May 2018 New trial record
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology